Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $92.8M | $128M | $164M | $193M | $200M | $201M |
| Revenue growth | — | 37.8% | 28.2% | 17.7% | 3.9% | 0.5% |
| Gross profit | $51.7M | $79.1M | $101M | $109M | $111M | $104M |
| Gross margin | 55.7% | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% |
| Operating income | $13.7M | $9.16M | -$1.80M | -$27.8M | -$20.5M | -$40.4M |
| Operating margin | 14.7% | 7.2% | -1.1% | -14.4% | -10.2% | -20.0% |
| Net income | $19.4M | $3.03M | $2.48M | -$12.1M | -$6.02M | -$66.5M |
| Net margin | 20.9% | 2.4% | 1.5% | -6.3% | -3.0% | -33.0% |
| EPS (diluted) | $0.10 | $0.00 | $0.02 | -$0.09 | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $15.2M | $4.63M | -$12.2M | $5.28M | $25.4M | -$4.69M |
| Capital expenditures | $1.55M | $4.36M | $9.75M | $4.65M | $3.52M | $4.08M |
| Free cash flow | $13.6M | $266K | -$22.0M | $633K | $21.9M | -$8.77M |
| Share buybacks | — | $0.00 | $0.00 | $44.2M | $21.6M | $15.1M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $165M | $365M | $297M | $167M | $98.7M | $90.9M |
| Total assets | $220M | $463M | $519M | $494M | $500M | $462M |
| Total liabilities | $41.7M | $57.9M | $93.9M | $101M | $104M | $120M |
| Shareholders' equity | -$16.0M | $405M | $426M | $393M | $396M | $342M |
| Retained earnings | -$22.6M | -$19.6M | -$17.0M | -$29.2M | -$35.2M | -$102M |
| Shares (wtd avg diluted) | 32.6M | 81.5M | 139M | 135M | 131M | 128M |
Every figure is extracted from Cytek Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.